FRIDAY, Aug. 8, 2025 (HealthDay News) — A new weight loss pill made by Eli Lilly helped people lose a significant amount of ...

Lilly's second-quarter results reported Thursday were still more than fine: $15.5 billion in revenue beat Wall Street ...

Eli Lilly’s orforglipron cut body weight to a lesser extent than rival Novo Nordisk’s semaglutide, falling into analysts’ ...

Today’s Forbes Daily covers Eli Lilly’s historic loss, the new GPT-5 for OpenAI’s ChatGPT, reactions to Instagram’s new map ...

Shares of Novo Nordisk (NYSE:NVO), traded in Copenhagen, rose over 5% on Friday, extending gains from the previous session.

Novo Nordisk shares jumped more than 5% on Friday, extending Thursday’s rally, after Eli Lilly’s obesity pill data fell short of market expectations.

Novo Nordisk A/S climbed 3.72% during Friday's pre-market trading session, after rival Eli Lilly 's Phase 3 ATTAIN-1 trial for obesity drug, orforglipron trailed the Danish drug giant's semaglutide.

(Reuters) -European shares edged higher and were on track for their biggest weekly gain in 12 as investors assessed U.S.

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

In an 18-month clinical trial of the experimental GLP-1 pill orforglipron, about 60 percent of people lost at least 10 ...

Drugmaker Eli Lilly says their oral, daily GLP-1 pill, orforglipron, may offer similar weight loss results as weekly GLP-1 ...

Eli Lilly stock beats Q2 estimates with strong sales but faces competitive risks and high valuation. Here's why investors may ...